1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Decentralized Clinical Trials in Neurology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Decentralized Clinical Trials in Neurology Market, by Indication
8.1.1. Alzheimer's Disease
8.1.1.1. Market Revenue and Forecast
8.1.2. Parkinson's Disease
8.1.2.1. Market Revenue and Forecast
8.1.3. Multiple Sclerosis
8.1.3.1. Market Revenue and Forecast
8.1.4. Epilepsy
8.1.4.1. Market Revenue and Forecast
8.1.5. Stroke
8.1.5.1. Market Revenue and Forecast
8.1.6. Migraine
8.1.6.1. Market Revenue and Forecast
8.1.7. Neuromuscular Disorders
8.1.7.1. Market Revenue and Forecast
8.1.8. Others
8.1.8.1. Market Revenue and Forecast
9.1. Decentralized Clinical Trials in Neurology Market, by Trial Phase
9.1.1. Phase I
9.1.1.1. Market Revenue and Forecast
9.1.2. Phase II
9.1.2.1. Market Revenue and Forecast
9.1.3. Phase III
9.1.3.1. Market Revenue and Forecast
9.1.4. Phase IV
9.1.4.1. Market Revenue and Forecast
10.1. Decentralized Clinical Trials in Neurology Market, by Trial Model
10.1.1. Fully Decentralized Trials (DCT)
10.1.1.1. Market Revenue and Forecast
10.1.2. Hybrid Decentralized Trials
10.1.2.1. Market Revenue and Forecast
11.1. Decentralized Clinical Trials in Neurology Market, by Technology
11.1.1. Telemedicine Platforms
11.1.1.1. Market Revenue and Forecast
11.1.2. eConsent & eCOA Solutions
11.1.2.1. Market Revenue and Forecast
11.1.3. Wearable Devices & Remote Monitoring
11.1.3.1. Market Revenue and Forecast
11.1.4. eSource & Electronic Data Capture (EDC)
11.1.4.1. Market Revenue and Forecast
12.1. Decentralized Clinical Trials in Neurology Market, by End User
12.1.1. Pharmaceutical Companies
12.1.1.1. Market Revenue and Forecast
12.1.2. Biotechnology Companies
12.1.2.1. Market Revenue and Forecast
12.1.3. Academic & Research Institutes
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Indication
13.1.2. Market Revenue and Forecast, by Trial Phase
13.1.3. Market Revenue and Forecast, by Trial Model
13.1.4. Market Revenue and Forecast, by Technology
13.1.5. Market Revenue and Forecast, by End User
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Indication
13.1.6.2. Market Revenue and Forecast, by Trial Phase
13.1.6.3. Market Revenue and Forecast, by Trial Model
13.1.6.4. Market Revenue and Forecast, by Technology
13.1.6.5. Market Revenue and Forecast, by End User
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Indication
13.1.7.2. Market Revenue and Forecast, by Trial Phase
13.1.7.3. Market Revenue and Forecast, by Trial Model
13.1.7.4. Market Revenue and Forecast, by Technology
13.1.7.5. Market Revenue and Forecast, by End User
13.2. Europe
13.2.1. Market Revenue and Forecast, by Indication
13.2.2. Market Revenue and Forecast, by Trial Phase
13.2.3. Market Revenue and Forecast, by Trial Model
13.2.4. Market Revenue and Forecast, by Technology
13.2.5. Market Revenue and Forecast, by End User
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Indication
13.2.6.2. Market Revenue and Forecast, by Trial Phase
13.2.6.3. Market Revenue and Forecast, by Trial Model
13.2.7. Market Revenue and Forecast, by Technology
13.2.8. Market Revenue and Forecast, by End User
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Indication
13.2.9.2. Market Revenue and Forecast, by Trial Phase
13.2.9.3. Market Revenue and Forecast, by Trial Model
13.2.10. Market Revenue and Forecast, by Technology
13.2.11. Market Revenue and Forecast, by End User
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Indication
13.2.12.2. Market Revenue and Forecast, by Trial Phase
13.2.12.3. Market Revenue and Forecast, by Trial Model
13.2.12.4. Market Revenue and Forecast, by Technology
13.2.13. Market Revenue and Forecast, by End User
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Indication
13.2.14.2. Market Revenue and Forecast, by Trial Phase
13.2.14.3. Market Revenue and Forecast, by Trial Model
13.2.14.4. Market Revenue and Forecast, by Technology
13.2.15. Market Revenue and Forecast, by End User
13.3. APAC
13.3.1. Market Revenue and Forecast, by Indication
13.3.2. Market Revenue and Forecast, by Trial Phase
13.3.3. Market Revenue and Forecast, by Trial Model
13.3.4. Market Revenue and Forecast, by Technology
13.3.5. Market Revenue and Forecast, by End User
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Indication
13.3.6.2. Market Revenue and Forecast, by Trial Phase
13.3.6.3. Market Revenue and Forecast, by Trial Model
13.3.6.4. Market Revenue and Forecast, by Technology
13.3.7. Market Revenue and Forecast, by End User
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Indication
13.3.8.2. Market Revenue and Forecast, by Trial Phase
13.3.8.3. Market Revenue and Forecast, by Trial Model
13.3.8.4. Market Revenue and Forecast, by Technology
13.3.9. Market Revenue and Forecast, by End User
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Indication
13.3.10.2. Market Revenue and Forecast, by Trial Phase
13.3.10.3. Market Revenue and Forecast, by Trial Model
13.3.10.4. Market Revenue and Forecast, by Technology
13.3.10.5. Market Revenue and Forecast, by End User
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Indication
13.3.11.2. Market Revenue and Forecast, by Trial Phase
13.3.11.3. Market Revenue and Forecast, by Trial Model
13.3.11.4. Market Revenue and Forecast, by Technology
13.3.11.5. Market Revenue and Forecast, by End User
13.4. MEA
13.4.1. Market Revenue and Forecast, by Indication
13.4.2. Market Revenue and Forecast, by Trial Phase
13.4.3. Market Revenue and Forecast, by Trial Model
13.4.4. Market Revenue and Forecast, by Technology
13.4.5. Market Revenue and Forecast, by End User
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Indication
13.4.6.2. Market Revenue and Forecast, by Trial Phase
13.4.6.3. Market Revenue and Forecast, by Trial Model
13.4.6.4. Market Revenue and Forecast, by Technology
13.4.7. Market Revenue and Forecast, by End User
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Indication
13.4.8.2. Market Revenue and Forecast, by Trial Phase
13.4.8.3. Market Revenue and Forecast, by Trial Model
13.4.8.4. Market Revenue and Forecast, by Technology
13.4.9. Market Revenue and Forecast, by End User
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Indication
13.4.10.2. Market Revenue and Forecast, by Trial Phase
13.4.10.3. Market Revenue and Forecast, by Trial Model
13.4.10.4. Market Revenue and Forecast, by Technology
13.4.10.5. Market Revenue and Forecast, by End User
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Indication
13.4.11.2. Market Revenue and Forecast, by Trial Phase
13.4.11.3. Market Revenue and Forecast, by Trial Model
13.4.11.4. Market Revenue and Forecast, by Technology
13.4.11.5. Market Revenue and Forecast, by End User
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Indication
13.5.2. Market Revenue and Forecast, by Trial Phase
13.5.3. Market Revenue and Forecast, by Trial Model
13.5.4. Market Revenue and Forecast, by Technology
13.5.5. Market Revenue and Forecast, by End User
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Indication
13.5.6.2. Market Revenue and Forecast, by Trial Phase
13.5.6.3. Market Revenue and Forecast, by Trial Model
13.5.6.4. Market Revenue and Forecast, by Technology
13.5.7. Market Revenue and Forecast, by End User
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Indication
13.5.8.2. Market Revenue and Forecast, by Trial Phase
13.5.8.3. Market Revenue and Forecast, by Trial Model
13.5.8.4. Market Revenue and Forecast, by Technology
13.5.8.5. Market Revenue and Forecast, by End User
14.1. IQVIA
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. ICON plc
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Parexel
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Medpace
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Labcorp Drug Development
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Syneos Health
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. PPD
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Worldwide Clinical Trials
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Worldwide Clinical Trials
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Novotech
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
